Integra LifeSciences (NASDAQ:IART) Shares Up 9.1% – What’s Next?

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) traded up 9.1% during trading on Monday. The company traded as high as $13.97 and last traded at $13.91. Approximately 566,782 shares changed hands during trading, a decline of 39% from the average session volume of 922,816 shares. The stock had previously closed at $12.75.

Analysts Set New Price Targets

Several analysts have recently commented on IART shares. Citizens Jmp reduced their price target on shares of Integra LifeSciences from $25.00 to $22.00 and set a “market outperform” rating on the stock in a research report on Thursday, October 22nd. Wells Fargo & Company set a $13.00 price objective on Integra LifeSciences and gave the stock an “equal weight” rating in a research report on Thursday, October 22nd. Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d+)” rating in a research note on Monday, October 26th. Truist Financial set a $13.00 price target on Integra LifeSciences and gave the company a “hold” rating in a research note on Friday, October 23rd. Finally, Zacks Research lowered Integra LifeSciences from a “hold” rating to a “strong sell” rating in a research note on Monday, October 26th. Two investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Reduce” and an average price target of $16.12.

Integra LifeSciences Price Performance

The company has a market capitalization of $1.07 billion, a PE ratio of 80.52, a price-to-earnings-growth ratio of 0.50 and a beta of 1.28. The company has a debt-to-equity ratio of 1.67, a current ratio of 3.62 and a quick ratio of 2.21. The stock’s 50 day simple moving average is $14.83 and its 200-day simple moving average is $14.08.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Wednesday, October 21st. The life sciences company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.03. Integra LifeSciences had a net margin of 0.79% and a return on equity of 18.63%. The firm had revenue of $411.18 million during the quarter, compared to analysts’ expectations of $413.16 million. During the same quarter in the previous year, the business posted ($0.07) earnings per share. As a group, equities analysts forecast that Integra LifeSciences Holdings Corporation will post 2.34 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

Large investors have recently bought and sold shares of the stock. Inspire Investing LLC raised its position in Integra LifeSciences by 5.2% in the 3rd quarter. Inspire Investing LLC now owns 39,168 shares of the life sciences company’s stock valued at $638,000 after purchasing an additional 1,929 shares in the last quarter. Commonwealth Equity Services LLC increased its stake in shares of Integra LifeSciences by 1.9% during the third quarter. Commonwealth Equity Services LLC now owns 152,837 shares of the life sciences company’s stock worth $2,488,000 after buying an additional 2,889 shares during the period. Sequoia Financial Advisors LLC increased its stake in shares of Integra LifeSciences by 27.4% during the first quarter. Sequoia Financial Advisors LLC now owns 14,233 shares of the life sciences company’s stock worth $134,000 after buying an additional 3,059 shares during the period. Public Employees Retirement System of Ohio purchased a new stake in shares of Integra LifeSciences during the second quarter worth approximately $82,000. Finally, Integrated Wealth Concepts LLC acquired a new stake in Integra LifeSciences in the second quarter valued at approximately $84,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra’s neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.